Skip to main content
Top
Published in: Journal of General Internal Medicine 6/2015

01-06-2015 | Original Research

Risk for Tuberculosis Disease Among Contacts with Prior Positive Tuberculin Skin Test: A retrospective Cohort Study, New York City

Authors: Prabhu P. Gounder, MD, MPH, Tiffany G. Harris, PhD, MS, Holly Anger, MPH, Lisa Trieu, MPH, Jeanne Sullivan Meissner, MPH, Betsy L. Cadwell, MSPH, Elena Shashkina, PhD, Shama D. Ahuja, PhD, MPH

Published in: Journal of General Internal Medicine | Issue 6/2015

Login to get access

Abstract

Background

Patients with prior positive tuberculin skin test (TST) results may benefit from prophylaxis after repeat exposure to infectious tuberculosis (TB).

Objective

To evaluate factors associated with active TB disease among persons with prior positive TST results named as contacts of persons with infectious TB.

Design

Population-based retrospective cohort study.

Participants

A total of 2,933 contacts with prior positive TST results recently exposed to infectious TB identified in New York City’s TB registry during the period from January 1, 1997 through December 31, 2003.

Main Measurements

Contacts developing active TB disease ≤ 4 years after exposure were identified and compared with those who did not, using Poisson regression analysis. Genotyping was performed on selected Mycobacterium tuberculosis-positive isolates.

Key Results

Among contacts with prior positive TST results, 39 (1.3 %) developed active TB disease ≤ 4 years after exposure (≤2 years: 34). Risk factors for contacts that were independently associated with TB were age < 5 years (adjusted prevalence ratio [aPR] = 19.48; 95 % confidence interval [CI] = 7.15–53.09), household exposure (aPR = 2.60;CI = 1.30–5.21), exposure to infectious patients (i.e., cavities on chest radiograph, acid-fast bacilli on sputum smear; aPR = 1.9 3;CI = 1.01–3.71), and exposure to a U.S.-born index patient (aPR = 4.04; CI = 1.95–8.38). Receipt of more than1 month of treatment for latent TB infection following the current contact investigation was found to be protective (aPR = 0.27; CI = 0.08–0.93). Genotype results were concordant with the index patients among 14 of 15 contacts who developed active TB disease and had genotyping results available.

Conclusions

Concordant genotype results and a high proportion of contacts developing active TB disease within 2 years of exposure indicate that those with prior positive TST results likely developed active TB disease from recent rather than remote infection. Healthcare providers should consider prophylaxis for contacts with prior TB infection, especially young children and close contacts of TB patients (e.g., those with household exposure).
Literature
1.
go back to reference Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(RR-15):1–47. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54(RR-15):1–47.
2.
go back to reference American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172(9):1169–227. doi:10.1164/rccm.2508001. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172(9):1169–227. doi:10.​1164/​rccm.​2508001.
3.
go back to reference Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.PubMed Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106.PubMed
4.
go back to reference Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1–51. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49(RR-6):1–51.
5.
go back to reference New York City Department of Health and Mental Hygiene. Tuberculosis Clinical Policies and Protocols. 4th ed: New York City Department of Health and Mental Hygiene; March 2008. New York City Department of Health and Mental Hygiene. Tuberculosis Clinical Policies and Protocols. 4th ed: New York City Department of Health and Mental Hygiene; March 2008.
6.
go back to reference Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162(6):2033–8.CrossRefPubMed Marks SM, Taylor Z, Qualls NL, Shrestha-Kuwahara RJ, Wilce MA, Nguyen CH. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000;162(6):2033–8.CrossRefPubMed
7.
go back to reference Anger HA, Proops D, Harris TG, Jeihui L, Kreiswirth BN, Shashkina E, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. CID. 2012;54(9):1287–95.CrossRef Anger HA, Proops D, Harris TG, Jeihui L, Kreiswirth BN, Shashkina E, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. CID. 2012;54(9):1287–95.CrossRef
9.
go back to reference Li J, Munsiff SS, Agerton TB. Prevalence of tuberculin skin test positivity in clinical population in New York City. J Immigr Minor Health Center Minor Public Health. 2010;12(6):816–22. doi:10.1007/s10903-008-9204-9.CrossRef Li J, Munsiff SS, Agerton TB. Prevalence of tuberculin skin test positivity in clinical population in New York City. J Immigr Minor Health Center Minor Public Health. 2010;12(6):816–22. doi:10.​1007/​s10903-008-9204-9.CrossRef
10.
go back to reference Munsiff SS, Nielsen D, Fujiwara P. Clinical policies and protocols. 2004. Munsiff SS, Nielsen D, Fujiwara P. Clinical policies and protocols. 2004.
12.
go back to reference Warren RM, van der Spuy GD, Richardson M, Beyers N, Booysen C, Behr MA, et al. Evolution of the IS6110-based restriction fragment length polymorphism pattern during the transmission of Mycobacterium tuberculosis. J Clin Microbiol. 2002;40(4):1277–82.CrossRefPubMedCentralPubMed Warren RM, van der Spuy GD, Richardson M, Beyers N, Booysen C, Behr MA, et al. Evolution of the IS6110-based restriction fragment length polymorphism pattern during the transmission of Mycobacterium tuberculosis. J Clin Microbiol. 2002;40(4):1277–82.CrossRefPubMedCentralPubMed
13.
go back to reference Warren RM, van der Spuy GD, Richardson M, Beyers N, Borgdorff MW, Behr MA, et al. Calculation of the stability of the IS6110 banding pattern in patients with persistent Mycobacterium tuberculosis disease. J Clin Microbiol. 2002;40(5):1705–8.CrossRefPubMedCentralPubMed Warren RM, van der Spuy GD, Richardson M, Beyers N, Borgdorff MW, Behr MA, et al. Calculation of the stability of the IS6110 banding pattern in patients with persistent Mycobacterium tuberculosis disease. J Clin Microbiol. 2002;40(5):1705–8.CrossRefPubMedCentralPubMed
Metadata
Title
Risk for Tuberculosis Disease Among Contacts with Prior Positive Tuberculin Skin Test: A retrospective Cohort Study, New York City
Authors
Prabhu P. Gounder, MD, MPH
Tiffany G. Harris, PhD, MS
Holly Anger, MPH
Lisa Trieu, MPH
Jeanne Sullivan Meissner, MPH
Betsy L. Cadwell, MSPH
Elena Shashkina, PhD
Shama D. Ahuja, PhD, MPH
Publication date
01-06-2015
Publisher
Springer US
Published in
Journal of General Internal Medicine / Issue 6/2015
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-015-3180-2

Other articles of this Issue 6/2015

Journal of General Internal Medicine 6/2015 Go to the issue

Clinical Practice: Exercises in Clinical Reasoning

Exercises In Clinical Reasoning

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.